Clinical trial NCT06215846: A Clinical Study Evaluating the Safety and Efficacy of BioTTT001 in Patients with Malignant Solid Tumors
Official title: Phase I Clinical Study on the Safety, Tolerability, and Pharmacokinetics of Recombinant Human NsIL12 Oncolytic Adenovirus Injection (BioTTT001) in Patients with Malignant Solid Tumors
Study type: INTERVENTIONAL
Overall status: ENROLLING_BY_INVITATION
Phase: PHASE1
Conditions: Solid Tumor
Keywords: Oncolytic virus
IL-12
Adenovirus
Lead sponsor: Beijing Bio-Targeting Therapeutics Technology Co., Ltd
Sponsor class: INDUSTRY
First posted: 2024-01-22
Enrollment: 12
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a Phase 1 open-label study to evaluate the safety, tolerability, and pharmacokinetics of Recombinant Human nsIL12 Oncolytic Adenovirus Injection (BioTTT001) at dose of 5×10∧9VP、5×10∧10VP、5×10∧11VP in Patients With Malignant Solid Tumors. Subjects will be treated with a single dose of BioTTT001 Injection after the screening period.

Detailed description: This study is a single arm, open label, single center dose escalation trial. Three study drug dosage groups are pre-set, namely 5 × 10∧9VP、5 × 10∧10VP、 5 × 10∧11VP. According to the principle of dose escalation from low to high, the "3+3" dose escalation method is adopted. In theory, in order to protect the safety of the subjects, during the DLT observation phase of the same dose group, the first subject in each dose group can only be enrolled in the second subject after at least 2 weeks after administration. The DLT observation period for each subject is 28 days after the first administration, and the last subject in each dose group can only enter the next dose escalation after completing the DLT observation period. At least 3 subjects are enrolled in each dose group, and each subject only receives one corresponding dose.

Eligibility criteria: Inclusion Criteria:

1. Age range from 18 to 80 years old (including the threshold), no gender restrictions.
2. Patients with histologically and/or cytologically confirmed malignant solid tumors, who have experienced at least one-line standard treatment failure or intolerance, or lack standard treatment options. Focus on malignancies in the head and neck, colorectal cancer, skin malignancies, and cervical cancer.
3. At least one assessable lesion according to the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.
4. Assessed by the investigators to have lesions suitable for intratumoral injection (assessable lesions and intratumoral injection lesions can refer to the same lesion).

Exclusion Criteria:

1. Known allergy to the investigational drug or its components.
2. Previous treatment with other adenovirus drugs.
3. Patients with active autoimmune diseases (such as systemic lupus erythematosus, rheumatoid arthritis, etc.), except type 1 diabetes, hypothyroidism that only needs hormone replacement therapy, and skin diseases that do not need systemic treatment (such as vitiligo, psoriasis or alopecia).
4. Patients who have not recovered from the adverse reactions of previous treatments (the treatment-related toxicity ≤ grade 2, except for alopecia, pigmentation or other tolerable events judged by the investigator ).

Primary outcomes:
measure: Incidence of adverse events
timeFrame: 28 days within BioTTT001 injection
measure: MTD
timeFrame: 28 days within BioTTT001 injection
Secondary outcomes:
measure: Plasma Adenovirus (ADV) copies
timeFrame: 28 days within BioTTT001 injection
measure: ADV copies in various sites
timeFrame: 28 days within BioTTT001 injection
measure: Serum interleukin-12 (IL-12) level
timeFrame: 28 days within BioTTT001 injection
measure: Serum neutralizing antibody level
timeFrame: 28 days within BioTTT001 injection
measure: ORR
timeFrame: From date of the first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months
measure: DCR
timeFrame: From date of the first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months
measure: PFS
timeFrame: From date of the first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months
Other outcomes:
Locations:
city: Shenyang
country: China
facility: The First Affiliated Hospital of China Medical Univeristy
state: Liaoning
Study officials:
affiliation: The First Affiliated Hospital of China Medical Univeristy
name: Zhenning Wang, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: The First Affiliated Hospital of China Medical Univeristy
name: Funan Liu, MD
role: PRINCIPAL_INVESTIGATOR
References: